Wellington Management Group LLP Has $1.21 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)

Wellington Management Group LLP raised its holdings in Altimmune, Inc. (NASDAQ:ALT) by 27.5% in the third quarter, Holdings Channel reports. The fund owned 197,232 shares of the company’s stock after acquiring an additional 42,553 shares during the period. Wellington Management Group LLP’s holdings in Altimmune were worth $1,211,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Stifel Financial Corp lifted its holdings in shares of Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares in the last quarter. Centiva Capital LP bought a new stake in Altimmune in the 3rd quarter valued at $120,000. Bellevue Group AG boosted its stake in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares during the period. BNP Paribas Financial Markets increased its holdings in Altimmune by 318.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock worth $259,000 after purchasing an additional 32,072 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Altimmune by 546.8% in the 3rd quarter. FMR LLC now owns 51,060 shares of the company’s stock valued at $314,000 after purchasing an additional 43,166 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ALT has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Trading Up 3.5 %

NASDAQ:ALT opened at $8.18 on Friday. The stock has a market capitalization of $581.80 million, a PE ratio of -5.28 and a beta of 0.15. Altimmune, Inc. has a 1-year low of $5.28 and a 1-year high of $14.84. The firm has a fifty day simple moving average of $7.89 and a 200 day simple moving average of $7.10.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the business earned ($0.39) EPS. On average, equities analysts predict that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.